We chose to move forward with crizotinib because this drug had undergone the most thorough evaluation, with demonstrated efficacy against ALK+ ALCL in multiple studies from USA and European countries[8–11] at that time. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.